FDA Law Blog

JANUARY 6, 2022

In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. S&G Labs Haw., The Eliminating Kickbacks in Recovery Act (“EKRA”). 18 U.S.C. §

Lab Testing 52

Lab Testing Referral Individual Patient-Centered 52

FDA Law Blog

JANUARY 6, 2022

In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. S&G Labs Haw., The Eliminating Kickbacks in Recovery Act (“EKRA”). 18 U.S.C. §

Lab Testing 40

Lab Testing Individual Referral Patient-Centered 40

GeriPal

FEBRUARY 6, 2025

We now have biomarkers that can reasonably approximate the degree of amyloid build-up in the brain with a simple blood test. We have two new FDA-approved medications that reduce that amyloid buildup and modestly slow down the progression of the disease. Summary Transcript CME Summary Things are changing quickly in the Alzheimers space.

Primary Care 97

Primary Care Diagnosis Screening IT 97